Physician profile
Lizabeth Sheets
NPI 1144900861
$3,200.84
in general payments reported to CMS, 2019-2025
21 companies · $966 in 2025
The $966 reported for 2025 was more than what 80% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $352 · 2024: $1,883 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183 · Education: $18.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.79 |
| Education | $18.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.63 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $370.32 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $324.60 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $296.42 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $294.78 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $217.58 | 2023-2025 | Rexulti |
| Alkermes, INC. | $214.29 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Almatica Pharma LLC | $213.26 | 2023-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $165.98 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $135.58 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $117.64 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $80.59 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $39.82 | 2025 | Quviviq |
| Ironshore Pharmaceuticals INC. | $34.74 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.59 | 2024-2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $30.03 | 2025 | Jornay Pm |
| Neuronetics, INC. | $28.13 | 2025 | Neurostar Tms Therapy System |
| Indivior INC. | $25.82 | 2023 | Perseris |
| Neos Therapeutics, LP | $23.86 | 2025 | Adzenys Xr-Odt |
| Mdd US Operations, LLC | $20.84 | 2025 | |
| Noven Therapeutics, LLC | $19.34 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lizabeth Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.